Aptahem AB Logo

Aptahem AB

Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.

APTA | SPGR

Overview

Corporate Details

ISIN(s):
SE0022447173 (+2 more)
LEI:
549300IVD1BY4CJMSO40
Country:
Sweden
Address:
Norra Vallgatan 58, 211 22 Malmö
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aptahem AB is a clinical-stage biotechnology company that develops RNA-based pharmaceuticals, known as aptamers, for the treatment of acute, life-threatening conditions involving a combination of coagulation, inflammation, and tissue damage. The company's lead candidate, Apta-1, is in clinical development with a primary indication for sepsis, a condition with a significant unmet medical need and high mortality. Apta-1 features a unique multi-mechanistic profile to address the complex pathology of sepsis. Aptahem's technology leverages synthetically produced aptamers, which offer a highly specific and low-immunogenicity alternative to traditional antibodies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aptahem AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptahem AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptahem AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America NCNA
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom NFX
Nurix Therapeutics, Inc. Logo
Developing protein degradation medicines to treat cancer and autoimmune diseases.
United States of America NRIX
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary NUTEX
NutriBand Inc. Logo
Develops abuse-deterrent transdermal patches to make potent drug delivery safer.
United States of America NTRB
Nuvalent, Inc. Logo
Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.
United States of America NUVL
Nuvation Bio Inc. Logo
A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.
United States of America NUVB
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan 4565
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland OBSN
OCULAR THERAPEUTIX, INC Logo
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America OCUL

Talk to a Data Expert

Have a question? We'll get back to you promptly.